Q1 2026 · Example Medical Group
Program Overview
EMG's care gap closure rates are significantly below all-site benchmarks across all three structural heart disease pathways. 6 patients are currently awaiting physician review.
Urgent Actions
Pathway Performance
Tricuspid Regurgitation
-46pp
vs. all-site benchmark
EMG 29%Benchmark 75%
Primary bottleneck
57% of notifications actively declined by referring physician.
TR progression accelerates at moderate-severe: 10%/year without intervention. Female patients carry 1.6× higher progression risk yet are 20% less likely to receive follow-up echo.
📄 Khalique et al., JACC 2023
View in Pipeline
Mitral Regurgitation
-18pp
vs. all-site benchmark
EMG 10%Benchmark 28%
Primary bottleneck
56% of notifications lost to follow-up after 90 days with no recorded action.
COAPT trial: TEER reduces heart failure hospitalization by 47% at 2 years for secondary MR patients on maximally tolerated GDMT.
📄 COAPT Trial
View in Pipeline
Aortic Stenosis
-22pp
vs. all-site benchmark
EMG 29%Benchmark 51%
Primary bottleneck
Only 10 of 29 identified patients reached the clinic. Identification gap precedes the referral problem.
32% of moderate AS progresses to severe within 1 year. Moderate AS carries equivalent adverse outcome risk as severe — the "moderate" classification creates false reassurance.
📄 Salem et al., AJC 2024
Review in Queue
Opportunity Pipeline — Mild & Moderate Disease
The current pipeline only addresses severe disease. The higher ROI is upstream.
18 mild/moderate patients are identified but not in the active referral pipeline. Catching disease at moderate prevents the downstream harm and cost of late-stage intervention — and represents a significantly larger addressable population.
Tricuspid Regurgitation
7
mild/mod identified
3
overdue surveillance
~290
est. in panel
Mitral Regurgitation
5
mild/mod identified
~310
est. in panel
Aortic Stenosis
6
mild/mod identified
~340
est. in panel
Platform Impact to Date
2
Procedures completed
across 3 pathways
View →
+26 pts
Avg KCCQ improvement
at 6-month follow-up
View →
~1
HF hospitalizations est. averted
TRILUMINATE · COAPT data
View →
6
Patients awaiting review
in active queue
View →